|
GT Biopharma, Inc. (GTBP) DCF -Bewertung
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
GT Biopharma, Inc. (GTBP) Bundle
Vereinfachen Sie die Bewertung der GT Biopharma, Inc. (GTBP) mit diesem anpassbaren DCF -Taschenrechner! Mit Real GT Biopharma, Inc. (GTBP) -Befinanzierungen und einstellbaren Prognoseeingaben können Sie Szenarien testen und GT Biopharma, Inc. (GTBP) in Minuten aufdecken.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -25.0 | .0 | .0 | 6.0 | -14.4 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | .0 | 57.5 | 21.3 | 13.6 | .0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -25.0 | -57.5 | -21.3 | -7.6 | -14.4 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 5.3 | 32.0 | 16.5 | 14.0 | 4.0 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | 2.2 | 8.2 | 3.1 | 4.3 | 3.9 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -27.9 | -58.2 | -20.9 | -7.6 | -14.4 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -25.7 | 5.3 | -4.7 | 7.2 | -14.8 | -3.9 | .0 | .0 | .0 | .0 |
| WACC, % | 6.81 | 6.81 | 6.81 | 6.81 | 6.81 | 6.81 | 6.81 | 6.81 | 6.81 | 6.81 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -3.6 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -4 | |||||||||
| Net Debt | -4 | |||||||||
| Equity Value | 0 | |||||||||
| Diluted Shares Outstanding, MM | 2 | |||||||||
| Equity Value Per Share | 0.18 |
What You Will Receive
- Adjustable Forecast Parameters: Seamlessly modify key assumptions (growth %, margins, WACC) to explore various scenarios.
- Comprehensive Data: GT Biopharma, Inc.'s (GTBP) financial data pre-loaded to facilitate your analysis.
- Automated DCF Calculations: The template computes Net Present Value (NPV) and intrinsic value automatically.
- Tailored and Professional Design: A refined Excel model that meets your valuation requirements.
- Designed for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and enhancing efficiency.
Key Features
- Comprehensive GTBP Financials: Gain access to reliable pre-loaded historical data and future forecasts.
- Tailored Forecast Assumptions: Modify highlighted cells for key metrics like WACC, growth rates, and profit margins.
- Real-Time Calculations: Automatic updates for DCF, Net Present Value (NPV), and cash flow assessments.
- User-Friendly Dashboard: Clear charts and summaries to help you visualize valuation outcomes.
- Designed for All Skill Levels: A straightforward, intuitive layout suitable for investors, CFOs, and consultants.
How It Works
- 1. Access the Template: Download and open the Excel file containing GT Biopharma, Inc. (GTBP)'s preloaded data.
- 2. Modify Assumptions: Adjust critical inputs such as growth rates, WACC, and capital expenditures.
- 3. Analyze Results Instantly: The DCF model automatically computes intrinsic value and NPV.
- 4. Explore Scenarios: Evaluate various forecasts to investigate different valuation possibilities.
- 5. Present with Assurance: Deliver professional valuation insights to enhance your decision-making.
Why Choose This Calculator for GT Biopharma, Inc. (GTBP)?
- Accuracy: Utilizes real GT Biopharma financials to ensure precise data.
- Flexibility: Tailored for users to experiment and adjust inputs as needed.
- Time-Saving: Eliminate the need to construct a DCF model from the ground up.
- Professional-Grade: Crafted with the expertise and usability expected at the CFO level.
- User-Friendly: Intuitive design makes it accessible for users without extensive financial modeling skills.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling GT Biopharma, Inc. (GTBP) stock.
- Financial Analysts: Streamline valuation processes with ready-to-use financial models for GT Biopharma, Inc. (GTBP).
- Consultants: Deliver professional valuation insights on GT Biopharma, Inc. (GTBP) to clients quickly and accurately.
- Business Owners: Understand how biotech companies like GT Biopharma, Inc. (GTBP) are valued to guide your own strategy.
- Finance Students: Learn valuation techniques using real-world data and scenarios related to GT Biopharma, Inc. (GTBP).
What the Template Contains
- Pre-Filled Data: Includes GT Biopharma’s historical financials and forecasts.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
- Key Financial Ratios: Analyze GT Biopharma’s profitability, efficiency, and leverage.
- Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
- Clear Dashboard: Charts and tables summarizing key valuation results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.